Long-term Remission of Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa Syndrome.

Cutis

College of Medicine, Ohio State University, Columbus. Drs. Bechtel and Chung are from the Department of Dermatology. Dr. Chung also is from the Department of Pathology.

Published: June 2023

AI Article Synopsis

  • Pyoderma gangrenosum (PG), acne, and hidradenitis suppurativa (HS) combined form a poorly understood autoinflammatory condition known as the PASH syndrome, making treatment challenging.
  • A patient's 18-month struggle with refractory PG, linked to cystic acne and HS, resulted in sustained remission for 4 years through a combination treatment of adalimumab and cyclosporine.
  • The complexity of the PASH syndrome suggests multiple inflammatory pathways are involved, highlighting the need for more research to identify specific mechanisms and improve treatment strategies.

Article Abstract

Pyoderma gangrenosum (PG), acne, and hidradenitis suppurativa (HS)(PASH) syndrome is an autoinflammatory condition that is poorly characterized in the literature, and achieving extended remission has proven difficult. We report the case of a patient with a history of cystic acne and HS who was referred to dermatology for evaluation of refractory PG of 18 months' duration. After therapeutic refinement, remission was achieved and maintained for 4 years using adalimumab and cyclosporine. Treatment success generally is only achieved using multimodal therapies targeting various molecules of the innate immune system, suggesting that PASH syndrome may involve multiple pathways of the inflammatory cascade; however, current understanding of the disease mechanism is scarce. The distinct genotypic and immunologic abnormalities of PASH syndrome require further study to uncover the mechanisms that therapeutic regimens aim to interrupt. Multimodal therapy is necessary to control the autoinflammatory nature of this disease, and further reports of therapeutic successes are essential for advancement in understanding this debilitating condition.

Download full-text PDF

Source
http://dx.doi.org/10.12788/cutis.0797DOI Listing

Publication Analysis

Top Keywords

pyoderma gangrenosum
8
gangrenosum acne
8
acne hidradenitis
8
hidradenitis suppurativa
8
pash syndrome
8
long-term remission
4
remission pyoderma
4
syndrome
4
suppurativa syndrome
4
syndrome pyoderma
4

Similar Publications

Granulomatosis with polyangiitis (GPA) is a small-to-medium vessel vasculitis that can affect the skin, respiratory tract, kidneys and other organs. A rare cutaneous manifestation of GPA is pyoderma gangrenosum (PG)-like ulcerations, which can have debilitating and disfiguring consequences. We report the case of a man in his 40s with refractory PG-like ulcerations secondary to GPA, not responsive to conventional immunosuppression, who was successfully treated with rituximab.

View Article and Find Full Text PDF

Objective: Chronic non-bacterial osteomyelitis (CNO) is a rare autoinflammatory bone disease associated with other chronic inflammatory diseases such as familial Mediterranean fever (FMF), juvenile idiopathic arthritis (JIA), spondylarthropathies, inflammatory bowel disease (IBD), and pyoderma gangrenosum. We aimed to describe the clinical and follow-up characteristics of patients with CNO and to compare findings between patients with and without comorbidities.

Methods: The clinical records of patients with CNO who were followed up in our pediatric rheumatology clinic between 2018 and 2023 were reviewed.

View Article and Find Full Text PDF

Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by pustules that rapidly progress into ulcers that commonly affect the lower limbs. Recently, successful treatment of PG has been reported with anti-IL 17 treatments. However, there have also been several reports of "paradoxical" induction of new PG lesions after use of IL-17 inhibitors.

View Article and Find Full Text PDF

Pyoderma gangrenosum (PG) is a rare dermatosis characterised by necrotic ulcers with a predilection mainly for the lower legs. We report a case of a 67-year-old man with PG and severe ankle ankylosis complicated by rheumatoid arthritis (RA) treated with anti-tumor necrosis factor, adalimumab (ADA). He was referred to our hospital because his right ankle showed severe ulcers and blackening.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!